SCHEMBL832236

SCHEMBL832236

COC(=O)c1c(C(F)(F)F)cc(-c2ccc(Cl)c(Cl)c2)nc1Cl

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 3/20 0.47
ALDH1A1 P00352 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
KDM4E B2RXH2 1/20 0.44
PKM P14618 1/20 0.44
RCE1 Q9Y256 1/20 0.44
EIF4E P06730 3/20 0.43
TTR P02766 1/20 0.42
KMO O15229 3/20 0.42
SLC6A3 Q01959 4/20 0.41
SLC6A2 P23975 3/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
AKR1C3 P42330 1/20 0.41
AKR1C2 P52895 1/20 0.41
ABL1 P00519 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL829581 0.91 NOTUM (0.46) NOTUMALDH1A1L3MBTL1KDM4EKMO
SCHEMBL832221 0.88 MAPT (0.50) NOTUMALDH1A1L3MBTL1KDM4ESLC6A3
SCHEMBL831022 0.86 ALDH1A1 (0.47) NOTUMALDH1A1L3MBTL1KDM4ELMNA
SCHEMBL830774 0.86 SMN1; SMN2 (0.51) NOTUMALDH1A1L3MBTL1KDM4EMAPT
SCHEMBL830911 0.86 ALDH1A1 (0.47) NOTUMALDH1A1L3MBTL1KDM4EKMO
SCHEMBL832309 0.85 ALDH1A1 (0.46) NOTUMALDH1A1L3MBTL1KDM4ESLC6A3
SCHEMBL831503 0.82 ALDH1A1 (0.46) NOTUMALDH1A1L3MBTL1KDM4ELMNA
SCHEMBL831077 0.77 NOTUM (0.41) NOTUMALDH1A1L3MBTL1KDM4ELMNA
SCHEMBL830078 0.74 ALDH1A1 (0.46) ALDH1A1L3MBTL1EIF4ETTRKMO
SCHEMBL24985709 0.74 KMO (0.53) NOTUMALDH1A1L3MBTL1KDM4EPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143411-B2 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2012-03-27 US disclosed
US-8143411-B2 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2012-03-27 US disclosed
US-8143411-B2 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2012-03-27 US disclosed
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2010-09-16 US disclosed
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2010-09-16 US disclosed
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2010-09-16 US disclosed
WO-2009033561-A1 SUBSTITUTED 6-PHEYLNICOTINIC ACIDS AND THE USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use SLC5A6, FABP3, NAPRT NOTUM 761/4885ALDH1A1 1238/4885L3MBTL1 823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.